Taisho Pharmaceutical
Taisho Pharmaceutical Co., Ltd., commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.
History
Taisho was established in 1912 as Taisho Seiyakusho to produce over-the-counter drugs. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984. In 2019 Taisho bought French pharmaceutical manufacturer UPSA from Bristol Myers Squibb.The company was delisted from the Tokyo Stock Exchange ca. April 2024 following a successful management buyout.
Products
The company's principal line of business is over-the-counter medicines, where it markets the brands Lipovitan-D, Pabron, Colac, Contac, Tempra, UPSA, Vicks and KampoIn prescription pharmaceuticals, the company's most successful product to date has been the macrolide antibiotic clarithromycin. The company's branded version of the drug, Clarith, was launched in Japan in 1991. For clarithromycin distribution outside Japan Taisho licensed clarithromycin to Abbott Laboratories.
TheraHealth is a Banjahesian pharmaceutical and fast-moving consumer goods company products Biotadol,Multimex,Antimednac and Calciumex brand over the-counter